Wegovy vs Zepbound: Which Wins for Weight Loss?

You’ve probably seen both names in the same sentence a dozen times by now. Wegovy and Zepbound get mentioned together constantly, usually with a little shrug attached, as if they’re basically the same thing in different boxes. They’re not. They’re cousins, sure, but the differences actually matter when you’re trying to figure out which one to ask your doctor about.

This is educational information, not medical advice. GLP-1 and GLP-1/GIP medicines — including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity) — are prescription-only and must be prescribed and supervised by a licensed clinician. Versions sold online as “research use only” are not FDA-approved for human use. Never start, change, or stop a dose on your own, and never source or self-inject these drugs outside of legitimate medical care. Talk to your doctor or pharmacist first, especially if you take other medications, could become pregnant, or have a health condition.

Quick answer: Zepbound (tirzepatide) tends to produce more weight loss on average, and it’s the only one of the two also approved to treat obstructive sleep apnea. Wegovy (semaglutide) has the longer track record and a heart-disease approval that Zepbound doesn’t have. For most people the real deciding factors end up being insurance coverage, price, side-effect tolerance, and which one their pharmacy can actually keep in stock. Neither is a clear winner for everyone.

What is your main goal?

Lose weight Gain muscles Eat healthy Explore new cuisines

Powered by DietGenie

What they actually are

Both are weekly injections you give yourself with a small pen, and both belong to the family of drugs people loosely call “GLP-1s.” But under the hood they’re built differently.

Wegovy is semaglutide at the 2.4 mg dose, made by Novo Nordisk. It mimics a single gut hormone called GLP-1, which nudges your body to feel full sooner, slows how fast your stomach empties, and quiets the food chatter a lot of people describe. Semaglutide is the same molecule inside Ozempic and Rybelsus, just at different doses and approved for different uses.

Zepbound is tirzepatide, made by Eli Lilly. It does the GLP-1 thing too, but it also hits a second hormone receptor called GIP. That dual action is the headline difference. Same molecule as Mounjaro, by the way, just branded and approved specifically for weight management. If you want to go deeper on the molecules themselves, we get into the weeds in our semaglutide vs tirzepatide breakdown, and the Mounjaro vs Zepbound and Ozempic vs Wegovy pieces sort out the brand-name confusion.

Suggested read: Ozempic vs Mounjaro: How the Two Compare

How much weight you might lose

This is the number everyone wants, so let’s put it up front, with one honest caveat: these two drugs have never been compared head-to-head in a single large trial for weight loss. The figures below come from separate studies with different participants and slightly different lengths, so you can’t just subtract one from the other and call it the gap.

Here’s a tool that lets you ballpark your own trajectory before we get into the trial numbers.

In the SURMOUNT-1 trial, adults on tirzepatide lost an average of about 20.9% of their body weight over 72 weeks at the top dose.¹ In STEP 1, adults on semaglutide 2.4 mg lost an average of about 14.9% over 68 weeks.² So on paper, tirzepatide pulls ahead. That extra GIP action seems to add something real.

But averages hide a lot. Plenty of people on Wegovy lose 15, 20, even 25% and never feel a need to switch. Others barely respond to either drug. Your starting weight, your diet, how much you move, your sleep, your genetics, whether you can tolerate climbing to the higher doses — all of it shifts where you land. The trial average is a guidepost, not a promise. If you’re new to this whole category and want the bigger picture, the GLP-1 for weight loss overview lays out how these meds work and who they’re typically for.

Suggested read: Liraglutide vs Semaglutide: Daily vs Weekly GLP-1

Side by side

Side effects: more alike than different

If you were hoping one of these had a clean bill of health and the other was a misery machine, sorry. They feel pretty similar in practice. The most common complaints with both are gastrointestinal — nausea, diarrhea, constipation, sometimes vomiting, occasionally burping or reflux.³ For most people this is worst in the first few weeks and right after each dose increase, then it settles down as the body adjusts.

That’s exactly why both drugs start you low and step you up slowly. The 0.25 mg starting dose for Wegovy and the 2.5 mg starting dose for Zepbound aren’t meant to do much for your weight — they’re there to let your stomach get used to the idea. Rushing the titration is how people end up feeling awful and quitting. We go deeper on what to expect and how to ride it out in semaglutide side effects.

The rarer-but-serious stuff is also broadly shared across the class: pancreatitis, gallbladder problems, and a boxed warning about thyroid C-cell tumors based on rodent studies, which means neither is given to people with certain personal or family histories of thyroid cancer. This is the kind of thing your prescriber screens for before you ever pick up a pen, and it’s a big reason these aren’t drugs to source on your own.

One practical note: because tirzepatide often drives more appetite suppression, some people find they have to be deliberate about eating enough protein and not undereating to the point of fatigue or muscle loss. That’s a conversation to have with whoever’s supervising your treatment.

Suggested read: Trulicity (Dulaglutide): Uses, Weight, Side Effects

The sleep apnea factor

Here’s where the two genuinely split. Zepbound is approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy is not.

That’s not a marketing footnote. Obstructive sleep apnea is closely tied to excess weight, and for years the standard answers were a CPAP machine, surgery, or just losing weight somehow. Having a medication formally cleared to improve apnea — not only as a side effect of weight loss but as an actual approved indication — gives some people a reason to lean toward Zepbound regardless of the weight numbers. If you snore like a chainsaw, wake up exhausted, or already have an apnea diagnosis, this could tip the whole decision. We unpack the connection in GLP-1 for sleep apnea.

Wegovy has its own exclusive card, though. It’s approved to reduce the risk of major cardiovascular events — things like heart attack and stroke — in adults who have obesity or overweight plus established heart disease. So if your bigger worry is your heart rather than your sleep, the scales can tip the other way. Two drugs, two different “bonus” approvals, and which one matters more depends entirely on your body.

Cost, coverage, and supply

This is the unglamorous part that decides more cases than the trial data does. Both drugs carry high list prices, often well over a thousand dollars a month without insurance. What you actually pay depends on your plan, whether weight-loss meds are covered at all (a lot of plans still carve them out), manufacturer savings programs, and which pharmacies near you have stock.

A few things worth knowing:

• Coverage rules differ between the two even within the same insurer, so one might be on your formulary while the other isn’t. Always check both.
• The sleep apnea and heart-disease approvals can change the coverage math, because an insurer that won’t pay for “weight loss” sometimes will pay when there’s a qualifying condition attached.
• Supply has been bumpy for this whole category. The one your doctor prefers isn’t always the one the pharmacy can fill that month, and that practical reality ends up steering plenty of prescriptions.

Both makers run their own savings programs that can knock the price down for eligible people, so it’s worth asking your prescriber or pharmacist to walk through what applies to you specifically rather than assuming the sticker price is your price.

Suggested read: Saxenda (Liraglutide): How the Daily Shot Works

So which one should you ask about?

If you want the blunt version: Zepbound has the edge on average weight loss and is the obvious pick if sleep apnea is part of your picture. Wegovy makes more sense if heart-disease risk is your main concern, or simply if it’s the one your insurance covers and you can get reliably. Both work. Both are real tools, not magic, and both work far better paired with food and movement changes than as a standalone fix.

The thing not to do is decide this alone based on a comparison article — including this one. The right choice runs through your medical history, your other medications, your coverage, and a clinician who can actually examine you.

Bottom line

Tirzepatide (Zepbound) tends to produce more weight loss than semaglutide (Wegovy) in the trials we have, and it’s the only one approved for obstructive sleep apnea. Wegovy counters with a longer history and a cardiovascular-risk approval Zepbound lacks. Side effects are mostly the same — GI issues that fade after the early weeks and dose bumps. For most people, the deciding factor isn’t the science at all; it’s what your insurance covers, what you’ll pay, and what your pharmacy can keep on the shelf. Bring both names to your doctor, lay out your goals and your history, and let that conversation pick the winner.